Rezolute climbs after positive trial results for low blood sugar treatment
02/06/2026 12:26
BUZZ-Rezolute climbs after positive trial results for low blood sugar treatment ** Shares of drug developer Rezolute RZLT.O rise 4.7% to $3.78 premarket
** Co says it saw positive interim results in its late-stage trial testing the drug ersodetug in patients with tumor hyperinsulinism, a rare condition characterized by severely low blood sugar
** Co says six of eight participants have already met the main goal of achieving at least a 50% reduction from baseline in intravenous glucose requirements
** RZLT is midway through enrollment of the planned study sample size of 16 participants
** Up to last close, stock up 53% YTD
(Reporting by Christy Santhosh)